EA200300572A1 - COMBINED THERAPY OF ESTROGEN-DEPENDENT DISEASES - Google Patents

COMBINED THERAPY OF ESTROGEN-DEPENDENT DISEASES

Info

Publication number
EA200300572A1
EA200300572A1 EA200300572A EA200300572A EA200300572A1 EA 200300572 A1 EA200300572 A1 EA 200300572A1 EA 200300572 A EA200300572 A EA 200300572A EA 200300572 A EA200300572 A EA 200300572A EA 200300572 A1 EA200300572 A1 EA 200300572A1
Authority
EA
Eurasian Patent Office
Prior art keywords
estrogen
combined therapy
dependent diseases
dependent
testicles
Prior art date
Application number
EA200300572A
Other languages
Russian (ru)
Inventor
Динеш Пурандаре
Original Assignee
Фармация Энд Апджон Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Энд Апджон Компани filed Critical Фармация Энд Апджон Компани
Publication of EA200300572A1 publication Critical patent/EA200300572A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение касается комбинированной терапии эстроген-зависимых злокачественных опухолей у восприимчивых млекопитающих, включая человека, состоящей из этапов ингибирования гормональной продукции их яичек или яичников, соответственно, и введения указанному млекопитающему по меньшей мере одного ингибитора ароматазы.The present invention relates to a combination therapy of estrogen-dependent malignant tumors in susceptible mammals, including humans, consisting of the steps of inhibiting the hormonal production of their testicles or ovaries, respectively, and administering at least one aromatase inhibitor to said mammal.

EA200300572A 2000-11-16 2001-11-06 COMBINED THERAPY OF ESTROGEN-DEPENDENT DISEASES EA200300572A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71460500A 2000-11-16 2000-11-16
PCT/US2001/043847 WO2002039995A2 (en) 2000-11-16 2001-11-06 Combination therapy for estrogen-dependent disorders

Publications (1)

Publication Number Publication Date
EA200300572A1 true EA200300572A1 (en) 2004-06-24

Family

ID=24870727

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300572A EA200300572A1 (en) 2000-11-16 2001-11-06 COMBINED THERAPY OF ESTROGEN-DEPENDENT DISEASES

Country Status (16)

Country Link
EP (1) EP1341549A2 (en)
JP (1) JP2004536022A (en)
KR (1) KR20030051828A (en)
CN (1) CN1498112A (en)
AU (1) AU2002230464A1 (en)
BR (1) BR0115423A (en)
CA (1) CA2428249A1 (en)
CZ (1) CZ20031349A3 (en)
EA (1) EA200300572A1 (en)
IL (1) IL155817A0 (en)
MX (1) MXPA03004195A (en)
NO (1) NO20032206L (en)
NZ (1) NZ525720A (en)
PL (1) PL365904A1 (en)
WO (1) WO2002039995A2 (en)
ZA (1) ZA200303669B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
GB0506759D0 (en) * 2005-04-02 2005-05-11 Medical Res Council Combination treatment methods
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US20080261933A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
CN101775054B (en) * 2010-02-05 2012-12-26 常州佳尔科药业集团有限公司 Synthesis method of 4-hydroxyl-4-alkene-3-ketone steroide compound

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9911582D0 (en) * 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia

Also Published As

Publication number Publication date
NZ525720A (en) 2006-12-22
JP2004536022A (en) 2004-12-02
WO2002039995A3 (en) 2003-05-01
WO2002039995A9 (en) 2003-02-06
CA2428249A1 (en) 2002-05-23
NO20032206D0 (en) 2003-05-15
AU2002230464A1 (en) 2002-05-27
ZA200303669B (en) 2004-05-13
NO20032206L (en) 2003-07-15
EP1341549A2 (en) 2003-09-10
MXPA03004195A (en) 2003-09-22
CZ20031349A3 (en) 2004-05-12
PL365904A1 (en) 2005-01-10
WO2002039995A2 (en) 2002-05-23
KR20030051828A (en) 2003-06-25
BR0115423A (en) 2005-12-13
IL155817A0 (en) 2003-12-23
CN1498112A (en) 2004-05-19

Similar Documents

Publication Publication Date Title
DK1187918T4 (en) Tek antagonists
MXPA03002778A (en) ANTIANGIOGEN POLYPEPTIDES AND METHODS TO INHIBIT ANGIOGENESIS.
BRPI0207961A8 (en) USE OF EPOTHYLONE AND CAPECITABIN ANALOGS TO MANUFACTURE DRUG TO TREAT SOLID CANCEROUS TUMORS AND KIT COMPRISING THE SAID COMPOUNDS.
MY137766A (en) Exemestane as chemopreventing agent
DE60231439D1 (en) MITOTIC KINESINE HEMMER
DE60234278D1 (en) MITOTIC KINESINE HEMMER
HN2001000244A (en) SPIROPIRIMIDIN INHIBITORS - 2, 4, 6 - TRIONA METALOPROTEINASAS.
ATE303156T1 (en) USE OF GNRH ANALOGUE TO TREAT URINARY INCONTINENCE
SE9800836D0 (en) New Compounds
EA200800755A1 (en) IKK INHIBITORS INTRODUCED FOR THE TREATMENT OF ENDOMETRIOSIS
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
TR200101895T2 (en) Treatment of sexual ailments.
TR200101120T2 (en) Serine protease inhibitor
PT1390371E (en) OXAZOLO- AND FUROPYRIMIDINES AND THEIR USE IN MEDICINES AGAINST TUMORS
EA200500244A1 (en) TETRAPROPILAMMONIA TETRATIOMOLYBDAT AND RELATED COMPOUNDS FOR ANTIANGIOGENIC THERAPY
TR200003443T2 (en) Combination therapy for the treatment of impressive depression
EA200201276A1 (en) ARYLMETYLAMINE DERIVATIVES FOR USE AS TRIPTASE INHIBITORS
ES2163795T3 (en) PHARMACEUTICAL COMPOSITION AGAINST TUMORS AND INFECTIONS BY PAPILOMAVIRUS.
ATE412412T1 (en) DERIVATIVES OF 3-HYDROXY-4-(CYCLYL-ALKYLAMINOALKYL)-5-PHENYL-1-PYRAZOLE AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH) FOR USE IN THE TREATMENT OF SEX HORMONAL DISEASES, SUCH AS PROSTATE OR MATERNAL CANCER
EA200300572A1 (en) COMBINED THERAPY OF ESTROGEN-DEPENDENT DISEASES
BR0114430A (en) Processes for cancer cell death induction and tumor regression
ATE489103T1 (en) TARGETED THROMBOSIS THROUGH TISSUE FACTOR POLYPEPTIDES
PA8453601A1 (en) FARNESIL TRANSFERASE INHIBITORS COMBINED WITH HMG COA REDUCTASE INHIBITORS FOR CANCER TREATMENT
TR200101693T2 (en) Treatment of follicular lymphomas using inhibitors of the lysophoxin (LT) expression pathway.
EE05241B1 (en) Use of the α-halogenoacryl derivative of distamycin